Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
TORONTO, ON / ACCESS Newswire / September 9, 2025 / Helix BioPharma Corp. (TSX:HBP)(OTC:HBPCF)(FRANKFURT:HBP0) ("Helix" or the "Company"), a clinical-stage...
Cancer
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage...
Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
New preclinical findings highlight Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene - often called...
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets
NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy...
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated...
Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer
HORGEN, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of...
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September...
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed...
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the...
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone...
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate...
New Data at American Foregut Society’s 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that...
20 Years of the Ubiquitin Revolution: Honoring Nobel Laureate Professor Avram Hershko and the Future of Targeted Protein Degradation
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD)...
Persephone Biosciences Unveils First-Of-Its-Kind Synbiotic Designed To Restore Critical Gut Microbes In Babies
Persephone Persephone - A First-Of-Its-Kind Synbiotic Newly released data shows that nine in ten babies lack critical gut microbes needed...
Biosplice Therapeutics Announces First Patient Dosed in NCI-Sponsored Clinical Trial of Cirtuvivint in Acute Myeloid Leukemia and Myelodysplastic Syndromes
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small...
Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor Heterogeneity Detection by Synergistic Combination of ctDNA and ISET® CTC-DNA in Patients with Early-Stage Lung Cancer
NEW YORK and PARIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rarecells, a pioneer in liquid biopsy technologies, today presented new...
RYBREVANT®▼ (amivantamab) en association avec LAZCLUZE®▼ (lazertinib) réduit la résistance acquise à l’osimertinib dans le traitement de première intention du cancer du poumon non à petites cellules avancé avec mutations de l’EGFR
De nouvelles données démontrent que l’association avec l’amivantamab réduit significativement les mutations courantes de résistance à l’EGFR et au MET...
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today...
LUMICKS launches Avidion to improve cell therapy development
Avidion brings clarity to immune drug-tumor interactions, helping scientists identify better cell therapy candidates, understand mechanisms, and advance with confidence....
Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division
Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in...